A cell function imaging method and application based on differences in glucose metabolism
By labeling DNA on tumor cells and combining DBCO-DNA with Beacon to generate fluorescence signals, expanding the difference in sugar metabolism, the problem of difficulty in distinguishing tumors from normal cells in the prior art is solved, and high-accurate tumor imaging is achieved, reducing Background signal interference.
Patent Information
- Application Number
- CN202211579554.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-09
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-12-09
AI Technical Summary
Existing functional imaging technologies are difficult to effectively distinguish between tumor cells and normal cells, resulting in background signal interference and reducing the accuracy of imaging.
Orthotopically enhanced functional imaging method based on sugar metabolism differences was used to label DNA on tumor cell membranes through click chemical reactions, and two adjacent DBCO-DNAs were used to combine with Beacon to generate fluorescence signals, expanding metabolic differences and reducing background signals.
It significantly improves the signal difference between tumor cells and normal cells, improves the accuracy and sensitivity of imaging, reduces false positives for normal cells, is universal and versatile, and is suitable for imaging detection and clinical applications of various types of tumors.
Smart Images

Figure CN115808410B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological imaging, and in particular to a cell function imaging method and application based on sugar metabolism differences. Background Art
[0002] Functional imaging technology has become a new milestone in the field of tumor imaging after computed tomography (CT) and magnetic resonance imaging (MRI). Unlike CT and MRI, which directly display the physical shape of the tumor, functional imaging technology can develop images based on the specific functions of the tumor, including the level of material and energy metabolism of the tumor that is different from that of normal tissue. Currently, functional imaging represented by positron emission tomography (PET) has been widely used in the clinical diagnosis of tumors. Based on the fact that the level of aerobic glycolysis in tumor tissue is higher than that in normal tissue, and that tumor cells require a large amount of hexose to provide energy for their physiological activities (including proliferation, migration, invasion, etc.), PET technology often uses the isotope F 18 Labeled glucose (FDG) is used as a contrast agent to visualize tumors by taking advantage of their higher sugar metabolism levels. For PET technology, differences in metabolic levels are the basis of functional imaging. The greater the difference, the more sensitive and contrast imaging results can be obtained. Under the guidance of the above principles, studying and finding metabolic pathways of substances with large differences and developing corresponding contrast agents are important research directions for functional imaging technology.
[0003] However, tumor cells do not have unified and unique characteristics at the molecular level and metabolic pathways. They only differ from other normal cells at the metabolic level. It is difficult to avoid the generation of background signals when performing functional imaging using only the relative differences in metabolism between tumors and normal tissues. If a strategy to enhance metabolic differences is constructed on this basis, there is a chance to improve the accuracy of functional imaging technology. Summary of the invention
[0004] In order to overcome the deficiencies of the prior art, the main purpose of the present invention is to provide a cell function imaging method based on differences in sugar metabolism, based on an imaging strategy for amplifying differences in sugar metabolism, i.e., adjacent enhanced functional imaging (PEFI), to construct an imaging method for amplifying differences in sugar metabolism levels between tumor cells and normal cells. Due to the need for rapid growth and division of tumor cells, they have a higher level of sugar metabolism than normal cells. If tumor cells and normal cells are fed with chemically labeled mannose, the chemical labels on the sugar chains of glycoproteins on the surface of tumor cell membranes will be much higher than those of normal cells. In this case, the probability of adjacent chemically labeled glycoproteins on the surface of tumor cells will be much higher than that of normal cells. At this time, if "two adjacent chemically labeled glycoproteins" are cleverly used as output signals, the output signals of tumor cells will be greatly improved, and relatively, the output signals of normal cells will be greatly reduced. This strategy of adjacent enhanced signals can multiply the metabolic differences, thereby reducing the background signal of the analysis and improving the accuracy.
[0005] Another object of the present invention is to provide the application of the above-mentioned cell function imaging method based on differences in sugar metabolism in the imaging detection and analysis of various types of tumors at the cellular level and the animal level. It has high accuracy in the imaging detection and analysis of various types of tumors in vitro and has important application value in the accurate identification and analysis of tumors in clinical tests.
[0006] The above-mentioned object of the present invention is achieved by the following technical solutions:
[0007] The first aspect of the present invention provides a cell function imaging method based on glucose metabolism difference, which performs proximity enhanced functional imaging based on the difference in glucose metabolism level between tumor cells and normal cells, uses two adjacent DNA-labeled glycoproteins as output signals, and multiplies the metabolic difference between tumor cells and normal cells through proximity enhanced signals. Specifically, the method comprises the following steps:
[0008] Step 1: construct DNA-engineered cells by using a sugar metabolism labeling method based on click chemistry, that is, after the cells are metabolized by tetraacylated-N-azidoacetyl-mannosamine (Ac4ManNAz), the sugar chains of their membrane proteins are labeled with azide (N3) groups;
[0009] Step 2: The DBCO-DNA modified DNA chain is attached to the N3 group on the cell membrane surface by a copper-free click chemistry reaction, wherein:
[0010] Two adjacent DBCO-DNAs on the cell membrane complementarily bind to a circular DNA (Circle), and Circle binds to a stem-loop DNA chain molecular beacon (Beacon) modified at the head and tail with TAMRA fluorescent group and BHQ2 quenching group, so that Beacon opens the stem-loop structure and outputs fluorescent signals at the two adjacent DBCO-DNAs on the cell membrane.
[0011] Preferably, the cell function imaging method based on differences in glucose metabolism comprises the following steps:
[0012] Step a: Design DBCO-DNA for cell surface engineering, Circle for binding to adjacent DNA on the cell membrane, and Beacon sequence for signal output;
[0013] Step b: The DBCO-DNA designed in step a is connected to the surface of tumor cells metabolized by Ac4ManNAz, and then the Circle and Beacon designed in step a are used to output signals on the cell surface for cell function imaging;
[0014] Step c: treating various tumor cell lines and normal cell lines with Ac4ManNAz for 1 to 84 hours, and comparing the changes in sugar metabolism levels between tumor cells and normal cells over metabolic time;
[0015] Step d: The treatment time at which the difference in glucose metabolism levels between the tumor cells and normal cells obtained in step c is the largest is taken as the glucose metabolism time, and the adjacent enhanced functional imaging of tumor cells based on the difference in glucose metabolism is completed through step b.
[0016] Preferably, in step a, the DBCO-DNA sequence used for cell surface engineering is:
[0017] 5'-DBCO-TTTTTTTTTTTTTTTTTTTTCAGAGTCAAGAGGAGTGAGT-3' (SEQ ID NO: 1).
[0018] Preferably, in step a, the Circle sequence used to bind to adjacent DNA on the cell membrane is:
[0019] 5'-CAGAGCAAGAGGGTGGGTTGGGGCAGTTTACTCACTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTCACTCCTTTTAGGGAGGGTTGGACAGATAGAGTG-3' (SEQ ID NO: 2).
[0020] Preferably, in step a, the Beacon sequence and group modification for outputting the signal are:
[0021] 5'-TAMRA-CGTGCGCTCTGCCCCAACCCACCCTCTTGCTCTGCACTCTATCTGTCCAACCCTCCCTAGCGCACG-BHQ2-3' (SEQ ID NO: 3).
[0022] Preferably, in step b, the adherent tumor cells are cultured in a medium containing 50 μM Ac4ManNAz for 72 h to metabolize the N3 group on the sugar chain of the cell membrane protein; then the medium is replaced with PBS containing 2 μM DBCO-DNA and incubated with the cells for 0.5 h to allow the DBCO-DNA to bind to the N3 group on the cell membrane through a click chemistry reaction to obtain DNA-engineered tumor cells; then the cells are reacted with PBS containing 2 μM Circle and PBS containing 2 μM Beacon for 0.5 h each; finally, the cells are photographed and imaged using a laser confocal microscope for image analysis.
[0023] Preferably, in step c, the adherently cultured tumor cells and normal cells are treated with a culture medium containing 50 μM Ac4ManNAz for 1 to 84 h, respectively, and then replaced with PBS containing 25 μM DBCO-Cy5 and incubated with the cells for 0.5 h. Finally, each group of cells is imaged using a laser confocal microscope, and the imaging results of tumor cells and normal cells at different glucose metabolism times are compared and analyzed using Image J software.
[0024] More preferably, in step c, the tumor cells include but are not limited to HeLa cells, A549 cells and HepG2 cells, and the normal cells include but are not limited to L02 cells, 293T cells and MCF10A cells.
[0025] Preferably, in step d, the treatment time when the difference in sugar metabolism levels between tumor cells and normal cells is the largest is used as the sugar metabolism time, that is, different tumor cells and normal cells are treated with a culture medium containing 50 μM Ac4ManNAz for 36 hours, and then reacted with PBS containing 2 μM DBCO-DNA for 0.5 hours. At this time, the DNA density on the surface of tumor cells is higher than that of normal cells, and the probability of DNA being adjacent to each other is also higher than that of normal cells; the subsequent operations are consistent with step b, and finally each group of cells is imaged using a laser confocal microscope, and each group of cells is analyzed using Image J software.
[0026] Another aspect of the present invention also provides the application of the above-mentioned cell function imaging method based on differences in sugar metabolism in in vitro tumor imaging detection and analysis.
[0027] Another aspect of the present invention also provides the application of the above-mentioned cell function imaging method based on differences in sugar metabolism in tumor imaging detection and analysis at the cellular level or animal level.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] 1. The present invention is based on the difference in sugar metabolism levels between tumor cells and normal cells, and constructs a cell function imaging based on sugar metabolism differences. Since tumor cells have higher metabolic efficiency and sialic acid expression than normal cells, the density of engineered DNA on the surface of tumor cells is much higher than that of normal cells, and the probability of DNA being adjacent to each other is also much higher than that of normal cells. Therefore, DBCO-DNA on the surface of tumor cells has a large amount and a high proximity rate, so a large number of fluorescent signals are generated on the tumor cell membrane; DBCO-DNA on the surface of normal cells is difficult to be adjacent due to its small amount, so that only a very small amount of fluorescent signals can be generated on the normal cell membrane. By using the adjacent enhanced functional imaging of tumor cells, accurate identification and analysis of tumor cells can be achieved, while the false positives of normal cells are greatly reduced.
[0030] 2. The PEFI technology used in the present invention is universal and general, and can accurately distinguish various types of tumor cells from normal cells.
[0031] 3. The PEFI technology used in the present invention has high accuracy in in vitro imaging detection and analysis of various types of tumors, and shows important clinical application value in the precise identification of various types of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Schematic diagram of constructing DNA engineered cells using the sugar metabolism labeling method based on click chemistry in the examples.
[0033] Figure 2 Schematic diagram of functional imaging of tumor cells and normal cells based on differences in sugar metabolism levels in the examples.
[0034] Figure 3 (a) Gel electrophoresis and (b) fluorescence intensity results of complementary binding of Circle and Beacon in the example.
[0035] Figure 4 This is the confocal imaging result of the proximity-enhanced functional imaging of HeLa cells in the example.
[0036] Figure 5The metabolic imaging results and fluorescence intensity analysis of Ac4ManNAz in tumor cells and normal cells at different times in the examples; (a) Schematic diagram of Ac4ManNAz metabolism analysis by fluorescence imaging; (b) Confocal imaging of Ac4ManNAz metabolism in tumor cells and normal cells over time; (c) Fluorescence intensity analysis of the confocal imaging in (b).
[0037] Figure 6 The confocal imaging results and fluorescence intensity analysis of PEFI imaging of various types of tumor cells and normal cells in the examples; (a) Confocal imaging of tumor cells and normal cells analyzed by PEFI; (b) Fluorescence intensity analysis of the confocal imaging in (a).
[0038] Figure 7 These are the imaging results before and after fluorescence-guided surgical resection of mouse abdominal tumor lesions using PEFI in the examples. DETAILED DESCRIPTION
[0039] The present invention is further described below in conjunction with specific examples. These examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0040] Example 1
[0041] This example provides a cell function imaging technology based on differences in glucose metabolism, including the following operations:
[0042] (1) Verification of the binding and signal output of Circle and Beacon: Mix Circle and Beacon in PBS, and the final concentration of both in the mixture is 500nM. Place the mixture in a 37°C constant temperature water bath in the dark for 0.5 to 1 hour. After the reaction, the conformational changes of Circle and Beacon after binding are analyzed by 15% non-denaturing polyacrylamide gel electrophoresis. The fluorescence intensity of Beacon after binding with Circle is analyzed by fluorescence spectrometer. The TAMRA fluorescent group modified in Beacon is excited with an excitation wavelength of 540nm, and the fluorescence intensity is detected in the wavelength range of 550nm to 700nm. The electrophoresis results are shown in the attached figure. Figure 3 As shown in a, after the mixture of Circle and Beacon, a new band appeared, indicating that Circle and Beacon complementarily combined to generate a new product; the fluorescence results are shown in the attached Figure 3 As shown in b, after adding Circle, Beacon changes from fluorescence quenching to fluorescence recovery state, proving that Circle can bind to and turn on Beacon, restoring its fluorescence.
[0043] (2) Cell culture: Human cervical cancer cells (HeLa cells), human non-small cell lung cancer cells (A549 cells), human liver cancer cells (HepG2 cells) and human embryonic kidney cells (293T) were cultured in DMEM medium containing 10% fetal bovine serum and 1% antibiotics (streptomycin and penicillin); human normal liver cells (L02 cells) were cultured in RPMI-1640 medium containing 10% fetal bovine serum and 1% antibiotics (streptomycin and penicillin); human mammary epithelial cells (MCF10A cells) were cultured in complete mammary epithelial cell culture medium. All cells were cultured in a constant temperature cell culture incubator at 37°C containing 5% carbon dioxide.
[0044] (3) Cell function imaging based on differences in sugar metabolism: HeLa cells were placed in a glass-bottomed culture dish. After the cells adhered to the wall, the culture medium of each cell was replaced with a culture medium containing 50 μM Ac4ManNAz, and the cells were placed in an incubator for 72 h. After washing three times with D-PBS, 2 μM DBCO-DNA was added and incubated at 37°C for 0.5 h. After washing three times with D-PBS, 2 μM Circle was added to the cell surface and incubated at 37°C for 0.5 h. After removing Circle and washing three times with D-PBS, 2 μM Beacon was added and incubated at 37°C for 0.5 h. Three control groups were set up based on all the above conditions, namely, the unsugared group without Ac4ManNAz (woAc4ManNAz), the unDNA-engineered group without DBCO-DNA (woDBCO-DNA), and the non-output signal group without Circle (woCircle). The cells were fixed with 4% PFA for 10 minutes at room temperature in the dark, washed three times with D-PBS, stained with DAPI for 10 minutes at room temperature in the dark, and then washed three times with D-PBS. Finally, the cells were imaged using a laser confocal microscope. Figure 4 As shown in the figure, after PEFI analysis, obvious fluorescence signals were generated on the HeLa cell membrane. In other control groups, after Beacon was added without adding Ac4ManNAz, DBCO-DNA or Circle, there was no or only very weak fluorescence signal on the cell surface. The feasibility of PEFI was proved, that is, the cell surface DNA was first engineered by sugar metabolism labeling method, and then functional imaging analysis was performed by complementary assembly of Circle, Beacon and cell surface DNA. The lack of any condition (including sugar metabolism labeling, DNA engineering, Circle combination, etc.) would not produce fluorescence signals on the cell surface.
[0045] Example 2
[0046] This embodiment is based on the cell function imaging method in Example 1, and according to the difference in the glucose metabolism level between tumor cells and normal cells, provides an adjacent enhanced functional imaging technology for tumor cells, including the following operations:
[0047] (1) Analysis of differences in sugar metabolism levels: HeLa cells, A549 cells, HepG2 cells, L02 cells, 293T cells and MCF10A cells were placed in glass-bottomed culture dishes. After the cells adhered to the wall, the culture medium of each cell was replaced with a culture medium containing 50μM Ac4ManNAz, and the cells were placed in an incubator and cultured for 2 to 84 hours. The control group used cells cultured in a culture medium without Ac4ManNAz. After that, the culture medium was removed, the cells were washed three times with D-PBS, 25μM DBCO-Cy5 was added to the dish and incubated at 37°C in the dark for 0.5h. The reaction solution was removed again, washed three times with D-PBS, 4% paraformaldehyde (PFA) was added to the dish and the cells were fixed for 10 minutes at room temperature in the dark, and washed three times with D-PBS. Finally, the cell nuclei were stained with DAPI for 10 minutes at room temperature in the dark, and then washed three times with D-PBS. The cells were imaged using a laser confocal microscope, and the imaging results were analyzed using ImageJ software. The results are shown in Figure 2. Figure 5 As shown in the figure, as the metabolic time increases, the fluorescence intensity generated on the surface of the tumor cell group (HeLa cells, A549 cells and HepG2 cells) gradually increases, while the fluorescence of the normal cell group (L02 cells, 293T cells and MCF10A cells) initially increases slowly and only increases significantly after 60 hours. The fluorescence intensity analysis shows that the relative fluorescence difference is the largest when the two groups of cells metabolize for about 36 hours, that is, the difference in sugar metabolism levels between tumor cells and normal cells is the largest when the sugar metabolism time is 36 hours.
[0048] (2) Proximity-enhanced cell function imaging: HeLa cells, A549 cells, HepG2 cells, L02 cells, 293T cells, and MCF10A cells were passaged separately, and 1×10 4 The cells were seeded in a confocal glass-bottomed dish. After the cells adhered, they were metabolized in a medium containing 50μM Ac4ManNAz for 36 hours. After washing three times with DPBS, 2μM DBCO-DNA was added and incubated at 37°C for 0.5h. After washing three times with DPBS, 2μM Circle was added to the cell surface and incubated at 37°C for 0.5h. After removing Circle and washing three times with DPBS, 2μM Beacon was added and incubated at 37°C for 0.5h. The cells were fixed with 4% paraformaldehyde and stained with DPAI. Finally, the cells were imaged using a laser confocal microscope, and the imaging results were analyzed using Image J software. The results are shown in Figure 2. Figure 6As shown in the figure, for tumor cells HeLa cells, A549 cells and HepG2 cells, obvious fluorescence signals can be observed on their surfaces; while for normal cells L02 cells, 293T cells and MCF10A cells, almost no fluorescence signals can be observed on their surfaces. The results of fluorescence statistical analysis also confirmed that the fluorescence intensity of the tumor cell group under PEFI analysis was much higher than that of the normal cell group. The results show that PEFI can convert the difference in metabolic levels between tumor cells and normal cells into the difference in the probability of adjacent DNA on the cell surface, thereby enhancing the signal output gap between the two cells, so that tumor cells can be accurately identified and analyzed, and false positives for normal cells can be reduced.
[0049] Example 3
[0050] This embodiment is based on Embodiment 1, and takes mouse peritoneal tumor imaging as an example, and uses PEFI technology for accurate identification and imaging of tumor tissue in vivo at the animal level, including the following operations:
[0051] All animal experiments strictly followed the guidelines of the Institutional Animal Care and Use Committee. Mouse breast cancer cells 4T1-luciferase labeled (4T1-LUC cells) were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and then collected to 5×10 per 100 μL. 5 The cells were intraperitoneally injected into five-week-old SPF BALB / c female nude mice (about 18-20g). After 5 days, small tumor nodules formed in the mice, and Ac4ManNAz (40 mg / kg) was injected into the tail vein for three days. Then DBCO-LDNA (2μM, 10mL / kg) was injected into the tail vein. One day later, the mice were anesthetized, and the abdominal cavity was opened to spray a mixture of Circle (2μM, 10mL / kg) and Beacon (2μM, 10mL / kg) double-modified with Cy5 and BHQ2. After 10 minutes, the unbound DNA was rinsed with normal saline. The small animal imaging system was used to monitor the bioluminescence and fluorescence imaging of the abdominal tumors simultaneously. The results are shown in the figure. Figure 7 As shown in the figure, the fluorescence imaging results of the abdominal tumor site are basically consistent with the bioluminescence imaging results, and the fluorescence edge is clear and the background signal is weak, indicating that PEFI can effectively distinguish tumor tissue from normal tissue in vivo. The tumor lesion was surgically removed under the guidance of PEFI fluorescence, and then the abdomen was imaged again. The results showed that almost no fluorescence signal and bioluminescence signal were observed, proving that the tumor lesion had been accurately and completely removed under the guidance of fluorescence. This result shows that PEFI has potential application value in guiding clinical tumor resection surgery.
[0052] The above embodiment is based on the difference in the sugar metabolism level of tumor cells and normal cells, and constructs a neighboring enhanced functional imaging method based on sugar metabolism difference, which is used for tumor imaging analysis at the cellular level and animal level. First, the cells are treated with Ac4ManNAz to metabolize the N3 group on their surface; then DBCO-DNA is connected to N3 to perform cell surface DNA engineering, and then the adjacent membrane glycoprotein on the cell surface is generated by introducing the combination of Circle and Beacon. By evaluating the sugar metabolism level of Ac4ManNAz in tumor cells and normal cells, 36h is selected as the subsequent sugar metabolism time in tumors and normal cells, and by confocal fluorescence imaging, the metabolic difference between tumor cells and normal cells is converted into the difference in the probability of adjacent DNA on the cell surface, thereby accurately identifying and analyzing various types of tumor cells and reducing the false positive of normal cells. A mouse peritoneal tumor model was constructed at the animal level, and PEFI analysis was used to effectively distinguish tumor tissue from normal tissue, and it played a role in fluorescence guidance in tumor resection surgery, which has important application value in the accurate identification and analysis of tumors in clinical examinations.
[0053] The present invention is not limited to the above-mentioned embodiments, and various changes can be made according to the purpose of the invention and creation of the present invention, and various other cell imaging and animal imaging applications can be performed. Any changes, modifications, substitutions, combinations or simplifications made according to the spirit and principle of the technical solution of the present invention shall be equivalent replacement methods, and as long as they meet the purpose of the invention and do not deviate from the technical principle and inventive concept of the present invention, they shall fall within the protection scope of the present invention.
Claims
1. A cell function imaging method based on differences in sugar metabolism, characterized in that: The steps include: Step a: designing DBCO-DNA for cell surface engineering, Circle for binding to adjacent DNA on the cell membrane, and Beacon sequence for signal output; wherein the DBCO-DNA sequence for cell surface engineering is SEQ ID NO: 1, the Circle sequence for binding to adjacent DNA on the cell membrane is SEQ ID NO: 2, and the Beacon sequence for signal output is SEQ ID NO: 3; Step b: The DBCO-DNA designed in step a is connected to the surface of tumor cells metabolized by Ac4ManNAz, and the Circle and Beacon designed in step a are used to output signals on the surface of tumor cells for cell function imaging; Step c: Treat various tumor cell lines and normal cell lines with Ac4ManNAz for 1 to 84 h, and compare the changes in sugar metabolism levels between tumor cells and normal cells over metabolic time; Step d: the treatment time at which the difference in glucose metabolism levels between the tumor cells and normal cells obtained in step c is the largest is used as the glucose metabolism time, and the adjacent enhanced functional imaging of tumor cells based on the difference in glucose metabolism is completed through step b; Wherein, in step b, the adherent cultured tumor cells are cultured in a medium containing 50 μM Ac4ManNAz for 72 h, so that the N3 group is metabolized on the sugar chain of the cell membrane protein; then the medium is replaced with PBS containing 2 μM DBCO-DNA and incubated with the cells for 0.5 h, so that the DBCO-DNA is bound to the N3 group on the cell membrane through a click chemistry reaction, thereby obtaining DNA-engineered tumor cells; then the cells are reacted with PBS containing 2 μM Circle and PBS containing 2 μM Beacon for 0.5 h each; finally, the cells are photographed and imaged using a laser confocal microscope for image analysis; In step c, the adherent tumor cells and normal cells were treated with a medium containing 50 μM Ac4ManNAz for 1 to 84 h, and then replaced with PBS containing 25 μM DBCO-Cy5 and incubated with the cells for 0.5 h. Finally, each group of cells was imaged using a laser confocal microscope, and the imaging results of tumor cells and normal cells at different glucose metabolism times were compared and analyzed using Image J software; In step d, the treatment time when the difference in sugar metabolism levels between tumor cells and normal cells was the largest was used as the sugar metabolism time, that is, different tumor cells and normal cells were treated with culture medium containing 50 μM Ac4ManNAz for 36 h, and then reacted with PBS containing 2 μM DBCO-DNA for 0.5 h. At this time, the DNA density on the surface of tumor cells was higher than that of normal cells, and the probability of DNA being adjacent to each other was also higher than that of normal cells. The subsequent operations were consistent with step b, and each group of cells was imaged using a laser confocal microscope, and each group of cells was analyzed using Image J software.
2. The cell function imaging method based on glucose metabolism difference according to claim 1, characterized in that: The tumor cells include HeLa cells, A549 cells and HepG2 cells; and / or the normal cells include L02 cells, 293T cells and MCF10A cells.
3. Use of the cell function imaging method based on glucose metabolism differences according to claim 1 or 2 in in vitro tumor imaging detection and analysis, wherein in vitro includes cell level and animal level.
